Allergan Buys Global Rights To Serenity's Phase III Drug For Frequent Nighttime Urination
This article was originally published in The Pink Sheet Daily
Executive Summary
Allergan also will have right of first refusal for Ser-120 in pediatric bedwetting, though this use is in early stage development.